Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec;17(12):658.
doi: 10.1038/s41585-020-00399-0.

Neoadjuvant anti-CTLA4 and anti-PD1 blockade in advanced urothelial cancer

Rebecca Tregunna  1
Affiliations
Comment

Neoadjuvant anti-CTLA4 and anti-PD1 blockade in advanced urothelial cancer

Rebecca Tregunna. Nat Rev Urol. 2020 Dec.
No abstract available

PubMed Disclaimer

Comment on

  • Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.
    van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, van Montfoort ML, van Rooijen C, Peters D, Broeks A, van der Poel HG, Bruining A, Lubeck Y, Sikorska K, Boellaard TN, Kvistborg P, Vis DJ, Hooijberg E, Schumacher TN, van den Broek M, Wessels LFA, Blank CU, van Rhijn BW, van der Heijden MS. van Dijk N, et al. Nat Med. 2020 Dec;26(12):1839-1844. doi: 10.1038/s41591-020-1085-z. Epub 2020 Oct 12. Nat Med. 2020. PMID: 33046870 Clinical Trial.

References

Original article
    1. van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. https://doi.org/10.1038/s41591-020-1085-z (2020) - DOI - PubMed

LinkOut - more resources